Login to Your Account



Pharma: Clinic Roundup


Friday, August 31, 2012
• Sosei Group Corp., of Tokyo, said QVA149 (indacaterol maleate/glycopyrronium bromide) met the primary endpoint in its fifth Phase III trial, which enrolled more than 2,000 subjects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription